Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C8H12N4 |
| Molecular Weight | 164.2077 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
C1CN(CCN1)C2=NC=CC=N2
InChI
InChIKey=MRBFGEHILMYPTF-UHFFFAOYSA-N
InChI=1S/C8H12N4/c1-2-10-8(11-3-1)12-6-4-9-5-7-12/h1-3,9H,4-7H2
| Molecular Formula | C8H12N4 |
| Molecular Weight | 164.2077 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
Approval Year
PubMed
| Title | Date | PubMed |
|---|---|---|
| Pharmacokinetic-pharmacodynamic modeling of buspirone and its metabolite 1-(2-pyrimidinyl)-piperazine in rats. | 2002 Dec |
|
| In vivo comparison of two 5-HT1A receptors agonists alnespirone (S-20499) and buspirone on locus coeruleus neuronal activity. | 2003 Jan 10 |
|
| A novel p38 alpha MAPK inhibitor suppresses brain proinflammatory cytokine up-regulation and attenuates synaptic dysfunction and behavioral deficits in an Alzheimer's disease mouse model. | 2007 Sep 4 |
|
| Mass spectrometry analysis of phosphopeptides after peptide carboxy group derivatization. | 2008 Nov 1 |
|
| Pharmacokinetic interaction between tandospirone and fluvoxamine in the rat contextual conditioned fear stress model and its functional consequence: Involvement of cytochrome P450 3A4. | 2008 Oct |
|
| A new strategy for antidepressant prescription. | 2010 |
|
| Synthesis and biological activity of some novel trifluoromethyl-substituted 1,2,4-triazole and bis(1,2,4-triazole) Mannich bases containing piperazine rings. | 2010 May 12 |
Patents
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 18:00:26 GMT 2025
by
admin
on
Mon Mar 31 18:00:26 GMT 2025
|
| Record UNII |
H3B5B38F56
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
244-135-5
Created by
admin on Mon Mar 31 18:00:26 GMT 2025 , Edited by admin on Mon Mar 31 18:00:26 GMT 2025
|
PRIMARY | |||
|
1078573
Created by
admin on Mon Mar 31 18:00:26 GMT 2025 , Edited by admin on Mon Mar 31 18:00:26 GMT 2025
|
PRIMARY | |||
|
Pyrimidinylpiperazine
Created by
admin on Mon Mar 31 18:00:26 GMT 2025 , Edited by admin on Mon Mar 31 18:00:26 GMT 2025
|
PRIMARY | |||
|
88747
Created by
admin on Mon Mar 31 18:00:26 GMT 2025 , Edited by admin on Mon Mar 31 18:00:26 GMT 2025
|
PRIMARY | |||
|
H3B5B38F56
Created by
admin on Mon Mar 31 18:00:26 GMT 2025 , Edited by admin on Mon Mar 31 18:00:26 GMT 2025
|
PRIMARY | |||
|
20980-22-7
Created by
admin on Mon Mar 31 18:00:26 GMT 2025 , Edited by admin on Mon Mar 31 18:00:26 GMT 2025
|
PRIMARY | |||
|
DTXSID00864967
Created by
admin on Mon Mar 31 18:00:26 GMT 2025 , Edited by admin on Mon Mar 31 18:00:26 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
TARGET -> INHIBITOR |
At small doses, 1-PP (ED50 = 80 ?g/kg, i.v.) reversed the depressant effect of the ?2-adrenoceptor agonist, clonidine
|
||
|
SALT/SOLVATE -> PARENT |
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
PARENT -> METABOLITE ACTIVE |
MAJOR
|
||
|
PARENT -> METABOLITE ACTIVE |
|
||
|
PARENT -> METABOLITE ACTIVE |
|
||
|
PARENT -> METABOLITE ACTIVE |
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
PARENT -> IMPURITY |
impurity detected at UV 240 nm
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
||
|
PARENT -> IMPURITY |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
